Form 8-K - Current report:
SEC Accession No. 0001390478-25-000017
Filing Date
2025-08-12
Accepted
2025-08-12 16:07:59
Documents
13
Period of Report
2025-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sls-20250812.htm   iXBRL 8-K 31668
2 EX-99.1 sls-202508128xkexhibit991.htm EX-99.1 79070
  Complete submission text file 0001390478-25-000017.txt   236570

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sls-20250812.xsd EX-101.SCH 1812
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sls-20250812_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sls-20250812_pre.xml EX-101.PRE 12529
15 EXTRACTED XBRL INSTANCE DOCUMENT sls-20250812_htm.xml XML 2733
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)